Zambia's Drug Cost-Sharing Proposed

14 July 1996

Zambian Health Minister Katele Kalumba has urged medical officials to develop a drug policy in which the cost of drugs would be shared between health institutions and patients. Speaking in Lusaka, he said a revolving fund for drugs should be set up to avoid government dependence on donors for their purchase, and he condemned the present system used by the tender board for awarding drugs contracts to health institutions based on price rather than quality.

Christer Agren of the Swedish Embassy in Zambia noted that the development of a national drug policy was an important step in dealing with some of the major problems in the country's health sector. Complex and potentially politically-sensitive issues needed to be addressed to improve the drug supply situation, he said. Sweden is supporting Zambia's health reforms through the Swedish International Development Agency.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight